AJMC® in the Press, April 12, 2019

The National Pharmaceutical Council’s Monday CER Daily Newsfeed included The American Journal of Managed Care^® (AJMC^®)'s coverage of the 2019 Community Oncology Conference. The article, “Pharma Discusses How to Reframe Value in Era of Precision Medicine, Combinations,” covered a session that found while healthcare experts may agree that the shift from volume to value is well under way, the definition of value has a different answer depending who you ask. Tuesday’s newsfeed included an AJMC^® interview with Daniel Ontaneda, MD, a neurologist at the Cleveland Clinic. During the interview, Ontaneda explained that there are 2 approaches for treating multiple sclerosis, and the DELIVER-MS study is the first to see which approach works better.

DocWire News’ article on generic drugs included the AJMC^® published study “Consumer Attitudes and Factors Related to Prescription Switching Decisions in Multitier Copayment Drug Benefit Plans,” which surveyed patients and found that most respondents did not believe that formulary drugs were safer or more effective than nonformulary drugs, but 39.7% believed formulary drugs were relatively less expensive. Most patients indicated that they were willing to consider switching from a nonformulary drug to a formulary drug for a lower copayment.